Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Adjuvant Radiochemotherapy
9%
Advisory Board
9%
Aggressive Treatment
9%
Astrocytic Tumor
9%
Blood-brain Barrier
9%
Brain Parenchyma
9%
Brain Systems
9%
Brain Tumor
9%
Brain Tumor Research
54%
Cancer Research
9%
Cancer Systems
54%
Cell Clones
9%
Central Nervous System
13%
Clinical Datasets
9%
Clinical Outcomes
13%
Clinical Significance
7%
Clinically Significant
9%
Clonal Evolution
13%
Computational Approach
13%
Computational Modeling
9%
Computational System
9%
Curative Treatment
9%
Cyclin-dependent Kinase 4 (CDK4)
9%
Data Integration
9%
Disease Progression
9%
Disease Resistance Mechanism
9%
Disease Subtypes
13%
DNA Methylation (DNAm)
13%
Drug Development
9%
Drug Testing
9%
Early-stage Researchers
9%
Economic Burden
9%
European Healthcare
9%
European Research
54%
Female Model
9%
Functional Assay
9%
Gender Analysis
9%
Gene Expression
13%
Gene mutation
9%
Genome Analysis
9%
Glial Cells
9%
Glioblastoma
100%
Glioblastoma Cells
5%
Glioblastoma Tumor
5%
Glioma
27%
Glioma Patients
72%
Grade IV Glioma
9%
Healthcare Sector
9%
Histopathological Features
7%
IDH-mutant Glioma
27%
IDH-wildtype
13%
Improved Patient Outcomes
18%
In Cancer
9%
Incurable Disease
13%
Initial Performance
9%
Innovative Research
9%
Innovative System
9%
Innovative Therapies
9%
Integrative multiomics
54%
Interdisciplinary Research
9%
International Academics
9%
Intersectoral Research
9%
Intracranial Implants
9%
Intratumoral Heterogeneity
27%
Intratumoral Treatment
27%
Isocitrate Dehydrogenase 1 (IDH1)
9%
Long-term Survivors
9%
Male Models
9%
Malignant Cells
9%
Mechanistic Understanding
9%
Medical Research Data
9%
MGMT Promoter Methylation
9%
Microglia
8%
Molecular Analysis
9%
Molecular Profiling
9%
Multi-omics
13%
Multiple Signals
9%
Murine Double Minute 2 (MDM2)
9%
Mutational Profiling
13%
Nervous System Tumors
9%
Next-generation Sequencing Technology
9%
Novel Context
13%
Novel Therapeutics
11%
Omics Dataset
9%
Omics Technologies
9%
Ongoing Trials
13%
Organoid Culture
9%
Organoids
40%
Orthotopic Xenograft
27%
Orthotopic Xenograft Model
13%
Pathway-specific
9%
Patient Avatars
27%
Patient Tumor
31%
Patient-derived Organoids
27%
Patient-derived Xenograft
77%
Performance Status
9%
Phenotypic Plasticity
5%
Precision Medicine
31%
Precision Oncology
27%
Precision Therapy
13%
Preclinical Tool
9%
Prefetcher
18%
Primary Glioma
27%
Primary Malignancy
13%
Proteogenomics
9%
Recurrent Glioma
27%
Resistant Cells
9%
Signal Transduction Pathway
9%
Single-cell RNA Sequencing (scRNA-seq)
27%
Single-cell Technologies
13%
Specific Genes
9%
Standard of Care
9%
Stratagem
13%
Surgical Adjuvants
9%
Surgical Removal
9%
Surgical Resection
9%
System Analysis
9%
Systemic Agents
9%
Systems Biology
9%
Systems Medicine
54%
Technological Approach
13%
Temozolomide
16%
Transcriptome
12%
Transcriptomic Adaptation
5%
Treatment Costs
9%
Treatment Resistance
36%
Treatment Strategy
13%
Treatment-resistant
9%
Tumor
43%
Tumor Biology
13%
Tumor Heterogeneity
9%
Tumor Incidence
9%
Tumor Microenvironment
27%
Tumor Organoids
9%
Tumor Patients
9%
Tumor-derived
9%
Unmet Needs
9%
Vulnerability
13%
WHO Grade IV
9%
Young Female Patients
9%
Biochemistry, Genetics and Molecular Biology
Alpha Thalassemia/Mental Retardation X-Linked
9%
Blood Brain Barrier
27%
Cancer Incidence
27%
Cancer Model
9%
Cell Clone
27%
Clinical Research
27%
Clinical Trial
9%
Clonal Evolution
36%
Computer Simulation
27%
Cyclin Dependent Kinase Inhibitor 2A
9%
Cyclin-Dependent Kinase
9%
Drug Development
27%
Drug Response
9%
Epidermal Growth Factor Receptor
27%
Gene Mutation
27%
Genetics
18%
Genomics
54%
Glial Cells
27%
IDH1
18%
In Vivo Study
27%
Methylation
27%
Microglia
45%
Multi-Omics
54%
Next Generation Sequencing
27%
Phenotypic Plasticity
9%
Platelet Derived Growth Factor Receptor Alpha
9%
Promoter Region
36%
Proteomics
27%
Rat
9%
RNA Sequence
27%
Signal Transduction
27%
Transcriptomics
36%
Vascularization
9%
Medicine and Dentistry
Adjuvant
6%
Blood Brain Barrier
6%
Cancer Incidence
6%
Cancer Research
61%
Chemoradiotherapy
6%
Clinical Research
6%
Clinician
13%
Disease Exacerbation
6%
Disease Resistance
6%
Diseases
13%
Drug Screening
6%
Ganglioglioma
34%
Gene Mutation
6%
Genetics
13%
Glioblastoma
54%
Health Care Cost
6%
Intracranial Tumor
54%
Malignant Neoplasm
54%
Methylation
6%
Microglia
6%
Molecular Profiling
6%
Multi-Omics
54%
Neoplasm
6%
Nervous System Tumor
6%
Next Generation Sequencing
6%
Organoid
27%
Parenchyma
6%
Promoter Region
6%
Proteomics
6%
Signal Transduction Pathway
6%
Somatics
6%
Surgery
6%
Systems Medicine
54%
Temozolomide
6%
Tumor
47%
Tumor Biology
6%
Xenograft
27%